UY30392A1 - Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c - Google Patents
Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis cInfo
- Publication number
- UY30392A1 UY30392A1 UY30392A UY30392A UY30392A1 UY 30392 A1 UY30392 A1 UY 30392A1 UY 30392 A UY30392 A UY 30392A UY 30392 A UY30392 A UY 30392A UY 30392 A1 UY30392 A1 UY 30392A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- hepatitis
- macrociclic
- oximyl
- protease inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de formula I, o sus sales aceptables para uso farmacéutico, ésteres, o prodorgas: que inhiben la actividad de serina proteasa, particularmente la actividad de la proteasa del virus de la hepatitis C (HCV) NS3-NS4A. En consecuencia, interfieren con el ciclo de vida del virus de la hepatitis C y también son utiles como agentes antivirales. Composiciones farmacéuticas que comprenden los compuestos mencionados para su administracion a un sujeto que sufra de una infeccion por HCV. Métodos para tratar una infeccion por HCV en un sujeto administrando una composicion farmacéutica que comprende los compuestos de la presente invencion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81146406P | 2006-06-06 | 2006-06-06 | |
US11/502,740 US20070281884A1 (en) | 2006-06-06 | 2006-08-11 | Macrocyclic oximyl hepatitis C protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30392A1 true UY30392A1 (es) | 2008-01-31 |
Family
ID=38791010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30392A UY30392A1 (es) | 2006-06-06 | 2007-06-06 | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070281884A1 (es) |
EP (1) | EP2037947A4 (es) |
JP (1) | JP4964950B2 (es) |
KR (1) | KR20090017688A (es) |
AR (1) | AR061238A1 (es) |
AU (1) | AU2007256622A1 (es) |
BR (1) | BRPI0712178A2 (es) |
CA (1) | CA2653034C (es) |
IL (1) | IL195515A0 (es) |
MX (1) | MX2008015495A (es) |
PE (1) | PE20080457A1 (es) |
RU (1) | RU2008152087A (es) |
TW (1) | TW200815482A (es) |
UY (1) | UY30392A1 (es) |
WO (1) | WO2007143694A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US9526769B2 (en) * | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20080187516A1 (en) * | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US8030307B2 (en) * | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
WO2009070692A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
US8268777B2 (en) * | 2007-12-05 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
WO2009076166A2 (en) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Oximyl hcv serine protease inhibitors |
WO2009073780A1 (en) * | 2007-12-06 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis c protease inhibitors |
AR070413A1 (es) | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
JP5490778B2 (ja) * | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
JP2012523419A (ja) | 2009-04-08 | 2012-10-04 | イデニク プハルマセウティカルス,インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
CA2821340A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2015004411A (es) | 2012-10-08 | 2016-04-06 | Abbvie Inc | Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). |
KR20150074051A (ko) | 2012-10-19 | 2015-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | C형 간염 바이러스 억제제 |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
CN113150076B (zh) * | 2021-03-03 | 2022-05-31 | 天津医科大学 | 环五肽的合成方法及其在抗丙肝药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE356105T1 (de) * | 2000-08-02 | 2007-03-15 | Uniroyal Chem Co Inc | Wiedergewinnung von nitroxyl-enthaltenden strömen bei niedriger temperatur |
WO2004072243A2 (en) * | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
NZ543250A (en) * | 2003-04-02 | 2008-12-24 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
WO2004093798A2 (en) * | 2003-04-18 | 2004-11-04 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
US8268776B2 (en) * | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
-
2006
- 2006-08-11 US US11/502,740 patent/US20070281884A1/en active Pending
-
2007
- 2007-06-06 PE PE2007000702A patent/PE20080457A1/es not_active Application Discontinuation
- 2007-06-06 RU RU2008152087/15A patent/RU2008152087A/ru not_active Application Discontinuation
- 2007-06-06 MX MX2008015495A patent/MX2008015495A/es not_active Application Discontinuation
- 2007-06-06 KR KR1020097000142A patent/KR20090017688A/ko not_active Application Discontinuation
- 2007-06-06 AU AU2007256622A patent/AU2007256622A1/en not_active Abandoned
- 2007-06-06 WO PCT/US2007/070524 patent/WO2007143694A2/en active Application Filing
- 2007-06-06 BR BRPI0712178-4A patent/BRPI0712178A2/pt not_active Application Discontinuation
- 2007-06-06 AR ARP070102427A patent/AR061238A1/es unknown
- 2007-06-06 TW TW096120283A patent/TW200815482A/zh unknown
- 2007-06-06 EP EP07812038A patent/EP2037947A4/en not_active Withdrawn
- 2007-06-06 JP JP2009514513A patent/JP4964950B2/ja not_active Expired - Fee Related
- 2007-06-06 CA CA2653034A patent/CA2653034C/en not_active Expired - Fee Related
- 2007-06-06 UY UY30392A patent/UY30392A1/es not_active Application Discontinuation
-
2008
- 2008-11-25 IL IL195515A patent/IL195515A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2008015495A (es) | 2009-03-23 |
RU2008152087A (ru) | 2010-07-20 |
EP2037947A4 (en) | 2010-04-21 |
IL195515A0 (en) | 2011-08-01 |
US20070281884A1 (en) | 2007-12-06 |
JP4964950B2 (ja) | 2012-07-04 |
CA2653034A1 (en) | 2007-12-13 |
AR061238A1 (es) | 2008-08-13 |
AU2007256622A1 (en) | 2007-12-13 |
PE20080457A1 (es) | 2008-06-25 |
TW200815482A (en) | 2008-04-01 |
EP2037947A2 (en) | 2009-03-25 |
KR20090017688A (ko) | 2009-02-18 |
CA2653034C (en) | 2011-11-01 |
JP2009539871A (ja) | 2009-11-19 |
WO2007143694A2 (en) | 2007-12-13 |
WO2007143694A3 (en) | 2008-11-20 |
BRPI0712178A2 (pt) | 2012-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
DOP2019000218A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
UY30527A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
ECSP10010254A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
UY38059A (es) | Heterociclos sustituidos como agentes antivirales | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
UY37997A (es) | Agentes antivirales contra la hepatitis b | |
UY28423A1 (es) | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- | |
MX2010010276A (es) | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. | |
MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
ECSP088258A (es) | Inhibidores de serina proteasas | |
MX2011012155A (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c. | |
MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
MX2009009176A (es) | Inhibidores de serina-proteasas. | |
UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170627 |